Clinical Trial Update: A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection [Phase 2]

View source ↗

Summary

Phase 2 study update on repeat dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for injection in severe hemophilia A; study status comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (pegylated recombinant coagulation factor VIII-Fc fusion protein)

Snippet

Sponsor: Jiangsu Gensciences lnc. | Conditions: Severe Hemophilia A | Phase 2 | Status: COMPLETED